Journal article
The value of 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).
- Le Rhun, Emilie Lille University Hospital, Lille, France;
- Weller, Michael Laboratory of Molecular Neuro-Oncology, Department of Neurology, and Neuroscience Center Zurich, University Hospital and University of Zurich, Zurich, Switzerland;
- Berghoff, Anna Sophie University of Vienna, Vienna, Austria;
- Rushing, Elisabeth Jane University Hospital Zurich, Department of Neuropathology, Zurich, Switzerland;
- Fuereder, Lisa Medical University of Vienna, Vienna, Austria;
- Petyt, Gregory Department of Nuclear Medicine, Lille University, Lille, France;
- Leske, Henning University Hospital Zurich, Zurich, Switzerland;
- Andrastschke, Nicolaus University Hospital Zurich, Zurich, Switzerland;
- Regli, Luca University Hospital Zurich, Zurich, Switzerland;
- Neidert, Marian Christoph University Hospital Zurich, Zurich, Switzerland;
- Stupp, Roger University Hospital Zurich and University of Zurich, Zurich, Switzerland;
- Dummer, Reinhard University of Zurich Hospital, Zurich, Switzerland;
- Frauenfelder, Thomas University Hospital Zurich, Zurich, Switzerland;
- Roth, Patrick Department of Neurology, University Hospital, Zürich, Switzerland;
- Reyns, Nicolas University Hospital Lille, Lille, France;
- Kaufmann, Philipp Antonio University Hospital Zurich, Zurich, France;
- Preusser, Matthias Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria;
- Wolpert, Fabian University Hospital Zurich, Zurich, Switzerland;
Published in:
- Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2017, vol. 35, no. 15_suppl, p. 2076-2076
English
2076 Background: Brain metastasis (BM) are the first clinical presentation of cancer in around 30% of patients. They are then referred as BM from cancer of unknown primary site (BM-CUPS). The value of 18 F-fluordesoxyglucose positron emission tomography (FDG-PET)/CT has not yet be determined for the management of these patients. Methods: A total of 566 patients were operated for BM at the University Hospital Zurich between 2004 and 2014, of whom 127 were identified as BM-CUPS patients. Two cohorts from other independent centers (n = 100 and 120) were used for the validation of data. Results: No difference in determining the localization of the primary lesion was observed between FDG-PET/CT and CT (FDG-PET/CT: 73/78, 93.6%; CT: n = 70/78, 89.7%; p = 0.25, McNemar’s test). The same pattern of primary lesion and other extracranial lesions was observed in 36 of 64 patients (56.3%). Additional suspicious extracranial metastases were identified by FDG-PET/CT in 28 patients (43.7%). The median graded prognostic assessment (GPA) scores were 2.5 determined according to FDG-PET/CT and 3 according to CT alone (p = 3.8x10-5 ), resulting in predicted survival times of 3.8 versus 5.3 months (p = 6.1x10-5 ; Wilcoxon’s test). Conclusions: A similar sensitivity of FDG-PET/CT and chest CT was observed for the detection of the primary tumor in BM-CUPS, however, FDG-PET/CT significantly improved the accuracy of staging. FDG-PET/CT should be preferred for the management of BM-CUPS and may help to avoid redundant CT imaging.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1200/jco.2017.35.15_suppl.2076
- ISSN 0732-183X
- Persistent URL
- https://sonar.rero.ch/global/documents/250225
Statistics
Document views: 26
File downloads: